To read the full story, subscribe or sign in.

Cabaletta acquires global rights to CD19 binder from Iaso Bio in $162M deal

Oct. 18, 2022

Nanjing Iaso Biotherapeutics Co. Ltd. has out-licensed a fully human anti-CD19 binder to Cabaletta Bio Inc. in a deal worth up to $162 million.

BioWorld Asia Deals and M&A Immune China

Today's news in brief

BioWorld

BioWorld briefs for April 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 11, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Antibodies binding to spike proteins on the surface of SARS-CoV-2 virus

Australian researchers discover new compound to treat long COVID

BioWorld

Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans....

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...